Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
增强了对 Proteograph 产品套件的访问权限，并通过新的客户数据展示了其强大功能
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
加利福尼亚州雷德伍德城，2024年2月29日（环球新闻专线）——将颠覆性蛋白质组学新平台商业化的领先生命科学公司Seer, Inc.（纳斯达克股票代码：SEER）今天公布了截至2023年12月31日的第四季度和全年财务业绩。
Recent Highlights
近期亮点
- Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the full year 2023, an increase of 8% over the full year 2022
- Shipped 23 instruments during 2023, bringing cumulative instruments shipped to 62 as of December 31, 2023
- Expanded internationally with the addition of four new distributors and partners
- First peer-reviewed customer publication in Nature Communications, demonstrating the power of the Proteograph in pQTL analysis
- Launched the Protein Discovery Catalog with over 10,000 proteins across 1,900 pathways to empower researchers
- Ended the year with approximately $373 million of cash, cash equivalents and investments
- 2023年第四季度实现收入440万美元，比2022年第四季度下降4％，2023年全年收入1,670万美元，比2022年全年增长8％
- 2023 年出货了 23 台仪器，使截至2023年12月31日的累计出货量达到62台
- 通过增加四家新的分销商和合作伙伴向国际扩张
- 第一份经过同行评审的客户出版物 《自然通讯》， 展示了 Proteograph 在 pqTL 分析中的力量
- 推出了蛋白质发现目录，其中包含跨越1,900种途径的10,000多种蛋白质，为研究人员提供支持
- 年底拥有约3.73亿美元的现金、现金等价物和投资
"In 2023, our customers continued to demonstrate the powerful biological insight that is uniquely possible by leveraging the Proteograph Product Suite. Recently, we saw our first customer study published in Nature Communications and we expect several more this year," said Omid Farokhzad, Chair and CEO. "Looking ahead, we are laser focused on translating the incredible performance of our platform and the uniqueness of the data it generates into widespread commercial adoption. I continue to be confident in the substantial long-term opportunity ahead and look forward to updating on our progress throughout 2024."
“2023年，我们的客户继续展示通过利用Proteograph产品套件所具有的独特可能的强大生物学洞察力。最近，我们看到了发表在《客户研究》中的第一份客户研究 自然通讯 而且我们预计今年还会有几个。” 董事长兼首席执行官奥米德·法罗赫扎德说。“展望未来，我们全神贯注于将我们平台的惊人性能及其生成的数据的独特性转化为广泛的商业应用。我仍然对未来的巨大长期机遇充满信心，并期待在2024年期间了解我们的最新进展。”
Fourth Quarter 2023 Financial Results
2023 年第四季度财务业绩
Revenue was $4.4 million for the three months ended December 31, 2023, a 3.6% decrease from $4.6 million for the three months ended December 31, 2022. This decrease was primarily due to a decrease in lease revenue related to SP100 instruments, partially offset by an increase in service revenue. Product revenue for the fourth quarter of 2023 was $3.0 million, including $366 thousand of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $1.1 million, including $201 thousand of related party revenue, and primarily consisted of revenue related to the Seer Technology Access Center, and grant and other revenue was $258 thousand.
截至2023年12月31日的三个月，收入为440万美元，较截至2022年12月31日的三个月的460万美元下降了3.6％。这一下降主要是由于与 SP100 仪器相关的租赁收入减少，但部分被服务收入的增加所抵消。2023 年第四季度的产品收入为 300 万美元，包括 36.6 万美元的关联方收入，包括 SP100 仪器和消耗品套件的销售。服务收入为110万美元，包括20.1万美元的关联方收入，主要包括与Seer技术接入中心相关的收入，补助金和其他收入为25.8万美元。
Gross profit, inclusive of grant and other revenue, was $2.0 million and gross margin was 45.1% for the fourth quarter of 2023.
2023年第四季度，包括补助金和其他收入在内的毛利为200万美元，毛利率为45.1％。
Operating expenses were $24.2 million for the fourth quarter of 2023, including $7.6 million of stock-based compensation, a decrease of 11% as compared to $27.2 million, including $8.2 million of stock-based compensation, for the corresponding prior year period. The decrease in expenses was primarily driven by a decrease in product development costs related to the Proteograph Product Suite, including employee compensation and other related expenses.
2023年第四季度的运营支出为2420万美元，包括760万美元的股票薪酬，与去年同期的2720万美元（包括820万美元的股票薪酬）相比下降了11％。支出减少的主要原因是与Proteograph产品套件相关的产品开发成本的减少，包括员工薪酬和其他相关费用。
Net loss was $17.8 million for the fourth quarter of 2023, as compared to $22.5 million for the corresponding prior year period.
2023年第四季度的净亏损为1780万美元，而去年同期的净亏损为2,250万美元。
Full Year 2023 Financial Results
2023 年全年财务业绩
Revenue was $16.7 million for the year ended December 31, 2023, an 8% increase from $15.5 million for the year ended December 31, 2022. Product revenue for the full year 2023 was $12.9 million, including $4.4 million of related party revenue. Service revenue was $2.3 million, including $241 thousand of related party revenue, and grant and other revenue was $1.5 million.
截至2023年12月31日的年度收入为1,670万美元，较截至2022年12月31日止年度的1,550万美元增长了8％。2023年全年的产品收入为1,290万美元，其中包括440万美元的关联方收入。服务收入为230万美元，包括24.1万美元的关联方收入，补助金和其他收入为150万美元。
Gross profit, inclusive of grant and other revenue, was $8.5 million and gross margin was 51.1% for the full year 2023.
毛利，包括补助金和其他收入，为850万美元，2023年全年的毛利率为51.1％。
Operating expenses were $112.0 million for the full year 2023, including $34.4 million of stock-based compensation, as compared to $104.3 million, including $33.7 million of stock-based compensation, for the corresponding prior year period.
2023年全年的运营支出为1.12亿美元，包括3440万美元的股票薪酬，而去年同期为1.043亿美元，包括3,370万美元的股票薪酬。
Net loss was $86.3 million for the full year 2023, as compared to $93.0 million for the corresponding prior year period.
2023年全年的净亏损为8,630万美元，而去年同期的净亏损为9,300万美元。
Cash, cash equivalents and investments were $373.1 million as of December 31, 2023.
截至2023年12月31日，现金、现金等价物和投资为3.731亿美元。
2024 Guidance
2024 年指导方针
Seer expects full year 2024 revenue to be in the range of $18 million to $20 million, representing growth of 14% at the midpoint over full year 2023.
Seer预计，2024年全年收入将在1,800万美元至2000万美元之间，相当于2023年全年中点增长14％。
Webcast Information
网络直播信息
Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
Seer将于太平洋时间2024年2月29日星期四下午 1:30 /美国东部时间下午 4:30 主持电话会议，讨论2023年第四季度和全年财务业绩。电话会议的网络直播可在以下网址观看 http://investor.seer.bio。网络直播将在活动结束后至少 90 天内存档并可供重播。
About Seer
关于先知
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer's Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer's Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Seer 是一家生命科学公司，开发变革性产品，为蛋白质组打开了新的门户。Seer的Proteograph Product Suite是一种集成解决方案，包括专有的工程纳米颗粒、消耗品、自动化仪器和软件，可在短短几个小时内大规模进行深入、无偏见的蛋白质组学分析。Seer 设计的 Proteograph 工作流程既高效又易于使用，利用广泛采用的实验室仪器提供几乎任何实验室都可以采用的分散式解决方案。Seer 的 Proteograph 产品套件仅用于研究用途，不适用于诊断程序。欲了解更多信息，请访问 www.seer.bio。
Forward Looking Statements
前瞻性陈述
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company's expectations for future results of operations and its financial position, business strategy, customer publications and adoption and outlook for fiscal year 2024. These and other risks are described more fully in Seer's filings with the Securities and Exchange Commission ("SEC") and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
本新闻稿包含经修订的1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。此类前瞻性陈述基于Seer的信念和假设以及截至本新闻稿发布之日其目前获得的信息。前瞻性陈述可能涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致Seer的实际业绩、业绩或成就与前瞻性陈述所表达或暗示的业绩、业绩或成就存在重大差异。这些声明包括但不限于有关公司对未来经营业绩的预期及其财务状况、业务战略、客户出版物以及2024财年的采用和展望的声明。Seer向美国证券交易委员会（“SEC”）提交的文件以及西尔随后不时向美国证券交易委员会提交的其他文件中对这些风险和其他风险进行了更全面的描述。除非法律要求，否则Seer没有义务更新此类声明以反映在声明发表之日后发生的事件或存在的情况。
Investor Contact:
Carrie Mendivil
investor@seer.bio
投资者联系人：
Carrie Mendivil
investor@seer.bio
Media Contact:
Patrick Schmidt
pr@seer.bio
媒体联系人：
帕特里克·施密特
pr@seer.bio
|
Seer, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) | |||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Revenue: | |||||||||||||||||||
| Product | $ | 2,669 | $ | 1,431 | $ | 8,506 | $ | 8,557 | |||||||||||
| Service | 944 | 708 | 2,016 | 913 | |||||||||||||||
| Related party | 567 | 1,720 | 4,660 | 5,215 | |||||||||||||||
| Grant and other | 258 | 745 | 1,479 | 808 | |||||||||||||||
| Total revenue | 4,438 | 4,604 | 16,661 | 15,493 | |||||||||||||||
| Cost of revenue: | |||||||||||||||||||
| Product | 1,663 | 785 | 5,398 | 5,459 | |||||||||||||||
| Service | 390 | 446 | 685 | 495 | |||||||||||||||
| Related party | 204 | 624 | 1,430 | 1,989 | |||||||||||||||
| Grant and other | 180 | 457 | 642 | 457 | |||||||||||||||
| Total cost of revenue | 2,437 | 2,312 | 8,155 | 8,400 | |||||||||||||||
| Gross profit | 2,001 | 2,292 | 8,506 | 7,093 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Research and development | 11,165 | 12,631 | 53,019 | 45,797 | |||||||||||||||
| Selling, general and administrative | 13,068 | 14,612 | 58,950 | 58,531 | |||||||||||||||
| Total operating expenses | 24,233 | 27,243 | 111,969 | 104,328 | |||||||||||||||
| Loss from operations | (22,232) | (24,951) | (103,463) | (97,235) | |||||||||||||||
| Other income (expense): | |||||||||||||||||||
| Interest income | 4,720 | 2,498 | 17,764 | 4,602 | |||||||||||||||
| Other expense | (287) | (73) | (578) | (333) | |||||||||||||||
| Total other income | 4,433 | 2,425 | 17,186 | 4,269 | |||||||||||||||
| Net loss | $ | (17,799) | $ | (22,526) | $ | (86,277) | $ | (92,966) | |||||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.28) | $ | (0.36) | $ | (1.35) | $ | (1.49) | |||||||||||
| Weighted-average common shares outstanding, basic and diluted | 64,157,125 | 62,805,423 | 63,850,490 | 62,433,613 | |||||||||||||||
| Seer, Inc. 合并运营报表 （以千计，股票和每股金额除外） | |||||||||||||||||||
| 截至12月31日的三个月 | 截至12月31日的财年 | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| 收入： | |||||||||||||||||||
| 产品 | $ | 2,669 | $ | 1,431 | $ | 8,506 | $ | 8,557 | |||||||||||
| 服务 | 944 | 708 | 2,016 | 913 | |||||||||||||||
| 关联方 | 567 | 1,720 | 4,660 | 5,215 | |||||||||||||||
| 格兰特等 | 258 | 745 | 1,479 | 808 | |||||||||||||||
| 总收入 | 4,438 | 4,604 | 16,661 | 15,493 | |||||||||||||||
| 收入成本： | |||||||||||||||||||
| 产品 | 1,663 | 785 | 5,398 | 5,459 | |||||||||||||||
| 服务 | 390 | 446 | 685 | 495 | |||||||||||||||
| 关联方 | 204 | 624 | 1,430 | 1,989 | |||||||||||||||
| 格兰特等 | 180 | 457 | 642 | 457 | |||||||||||||||
| 总收入成本 | 2,437 | 2,312 | 8,155 | 8,400 | |||||||||||||||
| 毛利 | 2,001 | 2,292 | 8,506 | 7,093 | |||||||||||||||
| 运营费用： | |||||||||||||||||||
| 研究和开发 | 11,165 | 12,631 | 53,019 | 45,797 | |||||||||||||||
| 销售、一般和管理 | 13,068 | 14,612 | 58,950 | 58,531 | |||||||||||||||
| 运营费用总额 | 24,233 | 27,243 | 111,969 | 104,328 | |||||||||||||||
| 运营损失 | (22,232) | (24,951) | (103,463) | (97,235) | |||||||||||||||
| 其他收入（支出）： | |||||||||||||||||||
| 利息收入 | 4,720 | 2498 | 17,764 | 4,602 | |||||||||||||||
| 其他费用 | (287) | (73) | (578) | (333) | |||||||||||||||
| 其他收入总额 | 4,433 | 2,425 | 17,186 | 4,269 | |||||||||||||||
| 净亏损 | $ | (17,799) | $ | (22,526) | $ | (86,277) | $ | (92,966) | |||||||||||
| 归属于普通股股东的每股净亏损，基本亏损和摊薄后 | $ | (0.28) | $ | (0.36) | $ | (1.35) | $ | (1.49) | |||||||||||
| 已发行普通股、基本股和摊薄后加权平均值 | 64,157,125 | 62,805,423 | 63,850,490 | 62,433,613 | |||||||||||||||
|
Seer, Inc. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 32,499 | $ | 53,208 | |||
| Short-term investments | 283,725 | 368,031 | |||||
| Accounts receivable, net | 4,831 | 4,315 | |||||
| Related party receivables | 559 | 1,804 | |||||
| Other receivables | 1,326 | 899 | |||||
| Inventory | 4,491 | 4,627 | |||||
| Prepaid expenses and other current assets | 3,082 | 2,098 | |||||
| Total current assets | 330,513 | 434,982 | |||||
| Long-term investments | 56,858 | 5,157 | |||||
| Operating lease right-of-use assets | 25,177 | 27,003 | |||||
| Property and equipment, net | 22,193 | 19,408 | |||||
| Restricted cash | 524 | 524 | |||||
| Other assets | 1,004 | 855 | |||||
| Total assets | $ | 436,269 | $ | 487,929 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,370 | $ | 2,104 | |||
| Accrued expenses | 9,212 | 8,298 | |||||
| Deferred revenue | 206 | 133 | |||||
| Operating lease liabilities, current | 2,295 | 1,842 | |||||
| Other current liabilities | 139 | 207 | |||||
| Total current liabilities | 13,222 | 12,584 | |||||
| Operating lease liabilities, net of current portion | 25,964 | 28,032 | |||||
| Other noncurrent liabilities | 179 | 320 | |||||
| Total liabilities | 39,365 | 40,936 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity: | |||||||
| Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of December 31, 2023 and 2022; zero shares issued and outstanding as of December 31, 2023 and 2022 | — | — | |||||
| Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of December 31, 2023 and 2022; 60,253,707 and 59,366,077 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 1 | 1 | |||||
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of December 31, 2023 and 2022; 4,044,969 shares issued and outstanding as of December 31, 2023 and 2022 |
— | — | |||||
| Additional paid-in capital | 702,868 | 667,739 | |||||
| Accumulated other comprehensive loss | (192) | (1,251) | |||||
| Accumulated deficit | (305,773) | (219,496) | |||||
| Total stockholders' equity | 396,904 | 446,993 | |||||
| Total liabilities and stockholders' equity | $ | 436,269 | $ | 487,929 | |||
| Seer, Inc. 合并资产负债表 （以千计，股票和每股金额除外） | |||||||
| 十二月三十一日 | |||||||
| 2023 | 2022 | ||||||
| 资产 | |||||||
| 流动资产： | |||||||
| 现金和现金等价物 | $ | 32,499 | $ | 53,208 | |||
| 短期投资 | 283,725 | 368,031 | |||||
| 应收账款，净额 | 4,831 | 4,315 | |||||
| 关联方应收款 | 559 | 1,804 | |||||
| 其他应收账款 | 1,326 | 899 | |||||
| 库存 | 4,491 | 4,627 | |||||
| 预付费用和其他流动资产 | 3,082 | 2,098 | |||||
| 流动资产总额 | 330,513 | 434,982 | |||||
| 长期投资 | 56,858 | 5,157 | |||||
| 经营租赁使用权资产 | 25,177 | 27,003 | |||||
| 财产和设备，净额 | 22,193 | 19,408 | |||||
| 限制性现金 | 524 | 524 | |||||
| 其他资产 | 1,004 | 855 | |||||
| 总资产 | $ | 436,269 | $ | 487,929 | |||
| 负债和股东权益 | |||||||
| 流动负债： | |||||||
| 应付账款 | $ | 1,370 | $ | 2,104 | |||
| 应计费用 | 9,212 | 8,298 | |||||
| 递延收入 | 206 | 133 | |||||
| 经营租赁负债，当前 | 2,295 | 1,842 | |||||
| 其他流动负债 | 139 | 207 | |||||
| 流动负债总额 | 13,222 | 12,584 | |||||
| 经营租赁负债，扣除流动部分 | 25,964 | 28,032 | |||||
| 其他非流动负债 | 179 | 320 | |||||
| 负债总额 | 39,365 | 40,936 | |||||
| 承付款和意外开支 | |||||||
| 股东权益： | |||||||
| 优先股，面值0.00001美元；截至2023年12月31日和2022年12月31日已获授权的500万股；截至2023年12月31日和2022年12月31日已发行和流通的股票为零 | — | — | |||||
| A类普通股，面值0.00001美元；截至2023年12月31日和2022年12月31日已授权94,000,000股；截至2023年12月31日和2022年12月31日分别已发行和流通的60,253,707股和59,366,077股股票 | 1 | 1 | |||||
| B 类普通股，面值0.00001美元；截至2023年12月31日和2022年12月31日已获授权6,000,000股；4,044,969股 截至 2023 年 12 月 31 日和 2022 年 12 月 31 日已发行和未偿还的 |
— | — | |||||
| 额外的实收资本 | 702,868 | 667,739 | |||||
| 累计其他综合亏损 | (192) | (1,251) | |||||
| 累计赤字 | (305,773) | (219,496) | |||||
| 股东权益总额 | 396,904 | 446,993 | |||||
| 负债和股东权益总额 | $ | 436,269 | $ | 487,929 | |||